19^th Global Nephrologists Annual Meeting

Biography

Biography: Vladimirs Strazdins

Abstract

Antimicrobial resistance is a growing worldwide problem. Urinary tract infection (UTI) is not an exception. Furthermore, the recent trends may prohibit the further use of fluoroquinolones in UTI treatment. Therefore, it is crucial to regularly update the bacterial flora spectrum data and the efficacy of the recommended empiric treatment to make timely and appropriate amendments where necessary. This observational study was comprised in July-November 2014, when family physicians across Latvia submitted the anonymous patient data on recurrent UTI treatment in their practice. Bacterial flora spectrum in Latvian adult recurrent UTI population was fairly consistent with data from other European countries, with prevalent Escherichia coli cultures. The soluble nitrofuran derivate (NFD) - in Latvia Furamags ® in particular was clinically effective in all patients, even in culture-negative or NFD-resistant patients. There was not a single case without any improvement in controlled parameters – Furamags ® was clinically effective in all cases, including pyelonephritis. This confirms unique multifactorial antibacterial activities of NFDs, which simultaneously inhibit protein synthesis, aerobic energy metabolism, DNA synthesis, RNA synthesis and cell-wall synthesis, thus ensuring antibacterial activity even against the seemingly resistant flora. The current first-choice empiric treatment of recurrent UTI by NFDs may stay unchanged. Particular NFD used in Latvia (Furamags ®) is safe, well-tolerated and effective first-line UTI (including pyelonephritis) treatment choice.